Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Melody Smith, Elena García-Martínez, Michael R. Pitter, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2018) Trial Watch: Toll-like receptor agonists in cancer immunotherapy. OncoImmunology 7:12.
Read now
Read now
Mitchell Evers, Margot Jak & J. H. W. Leusen. (2018) The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Expert Opinion on Biological Therapy 18:9, pages 973-982.
Read now
Read now
Articles from other publishers (28)
Prioty Islam. (2023) Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review. Current Treatment Options in Oncology.
Crossref
Crossref
Max Yano, John C. Byrd & Natarajan Muthusamy. (2022) Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential. Cancers 14:23, pages 5787.
Crossref
Crossref
Jennifer A. Woyach. (2022) Management of relapsed/refractory Chronic Lymphocytic Leukemia. American Journal of Hematology 97:S2.
Crossref
Crossref
Hao Guo, Jingyi Yang, Haoran Wang, Xingchen Liu, Yanyan Liu & Keshu Zhou. (2022) Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms. Frontiers in Immunology 13.
Crossref
Crossref
Tsung-Ying Yu, Hong-Jie Jhou, Po-Huang Chen & Cho-Hao Lee. (2022) Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis. Current Oncology 29:6, pages 4245-4259.
Crossref
Crossref
Vanessa Desantis, Francesco Domenico Savino, Antonietta Scaringella, Maria Assunta Potenza, Carmela Nacci, Maria Antonia Frassanito, Angelo Vacca & Monica Montagnani. (2022) The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value. Journal of Clinical Medicine 11:9, pages 2513.
Crossref
Crossref
Makhloufi Zoulikha & Wei He. (2022) Targeted Drug Delivery for Chronic Lymphocytic Leukemia. Pharmaceutical Research 39:3, pages 441-461.
Crossref
Crossref
Francesca Perutelli, Rebecca Jones, Valentina Griggio, Candida Vitale & Marta Coscia. (2022) Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges. Frontiers in Oncology 12.
Crossref
Crossref
Isaac Park, Tra Mi Phan & Jing Fang. (2021) Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q. Cancers 13:20, pages 5084.
Crossref
Crossref
Csilla Kriston, Márk Hernádfői, Márk Plander, Ágnes Márk, Ferenc Takács, Ágnes Czeti, Gábor Szalóki, Orsolya Szabó, András Matolcsy & Gábor Barna. (2021) Lenalidomide abrogates the survival effect of bone marrow stromal cells in chronic lymphocytic leukemia. Hematological Oncology 39:4, pages 513-520.
Crossref
Crossref
Clare Sun & Adrian Wiestner. (2021) Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?. Hematology/Oncology Clinics of North America 35:4, pages 827-845.
Crossref
Crossref
Candida Vitale, Elia Boccellato, Lorenzo Comba, Rebecca Jones, Francesca Perutelli, Valentina Griggio & Marta Coscia. (2021) Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia. Cancers 13:15, pages 3856.
Crossref
Crossref
Elisavet Vlachonikola, Kostas Stamatopoulos & Anastasia Chatzidimitriou. (2021) T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia. Cancers 13:13, pages 3255.
Crossref
Crossref
Hannah Wurzer, Liza Filali, Céline Hoffmann, Max Krecke, Andrea Michela Biolato, Jérôme Mastio, Sigrid De Wilde, Jean Hugues François, Anne Largeot, Guy Berchem, Jérôme Paggetti, Etienne Moussay & Clément Thomas. (2021) Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling. Frontiers in Immunology 12.
Crossref
Crossref
Ying Ying Keng, Kiam Heong Kwa & Kurunathan Ratnavelu. (2021) Centrality analysis in a drug network and its application to drug repositioning. Applied Mathematics and Computation 395, pages 125870.
Crossref
Crossref
Valentina Griggio, Francesca Perutelli, Chiara Salvetti, Elia Boccellato, Mario Boccadoro, Candida Vitale & Marta Coscia. (2020) Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. Frontiers in Immunology 11.
Crossref
Crossref
Catherine Hoofd, Steven J. Huang, Samuel Gusscott, Sonya Lam, Rachel Wong, Alexa Johnston, Susana Ben-Neriah, Christian Steidl, David W. Scott, Helene Bruyere, Tanya L. Gillan, Cynthia L. Toze, Alina S. Gerrie & Andrew P. Weng. (2020) Ultrasensitive Detection of NOTCH1 c.7544_7545delCT Mutations in Chronic Lymphocytic Leukemia by Droplet Digital PCR Reveals High Frequency of Subclonal Mutations and Predicts Clinical Outcome in Cases with Trisomy 12. The Journal of Molecular Diagnostics 22:4, pages 571-578.
Crossref
Crossref
Cho-Hao Lee, Yi-Ying Wu, Tzu-Chuan Huang, Chin Lin, Yi-Fen Zou, Ju-Chun Cheng & Ching-Liang Ho. (2019) Maintenance therapy for chronic lymphocytic leukaemia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Eva Leufven & Øystein Bruserud. (2019) Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments. Current Medicinal Chemistry 26:28, pages 5244-5261.
Crossref
Crossref
Tom Hofland, Eric Eldering, Arnon P. Kater & Sanne H. Tonino. (2019) Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences 20:17, pages 4315.
Crossref
Crossref
Arik Bernard Schulze, Georg Evers, Andrea Kerkhoff, Michael Mohr, Christoph Schliemann, Wolfgang E. Berdel & Lars Henning Schmidt. (2019) Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer. Cancers 11:5, pages 690.
Crossref
Crossref
Paolo StratiKoichi Takahashi, Christine B. Peterson, Michael J. KeatingPhilip A. ThompsonNaval G. Daver, Nitin JainJan A. Burger, Zeev Estrov, Susan M. O'BrienHagop M. Kantarjian, William G. WierdaP. Andrew Futreal & Alessandra Ferrajoli. (2019) Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Advances 3:9, pages 1533-1539.
Crossref
Crossref
Jim H. Hughes, Mitch A. Phelps, Richard N. Upton, Stephanie E. Reuter, Yue Gao, John C. Byrd, Michael R. Grever, Craig C. Hofmeister, Guido Marcucci, William Blum, Kristie A. Blum & David J.R. Foster. (2019) Population pharmacokinetics of lenalidomide in patients with B‐cell malignancies. British Journal of Clinical Pharmacology 85:5, pages 924-934.
Crossref
Crossref
Deyan Y. Yosifov, Christine Wolf, Stephan Stilgenbauer & Daniel Mertens. (2019) From Biology to Therapy: The CLL Success Story. HemaSphere 3:2, pages e175.
Crossref
Crossref
Ota Fuchs. (2019) Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs. Cardiovascular & Hematological Disorders-Drug Targets 19:1, pages 51-78.
Crossref
Crossref
Gerardo Ferrer & Emili Montserrat. (2018) Critical molecular pathways in CLL therapy. Molecular Medicine 24:1.
Crossref
Crossref
Kirsten Fischer & Michael Hallek. (2017) Optimizing frontline therapy of CLL based on clinical and biological factors. Hematology 2017:1, pages 338-345.
Crossref
Crossref
Anna Maria Fink, Jasmin Bahlo, Sandra Robrecht, Othman Al-Sawaf, Ali Aldaoud, Holger Hebart, Kathleen Jentsch-Ullrich, Steffen Dörfel, Kirsten Fischer, Clemens-Martin Wendtner, Thomas Nösslinger, Paolo Ghia, Francesc Bosch, Arnon P Kater, Hartmut Döhner, Michael Kneba, Karl-Anton Kreuzer, Eugen Tausch, Stephan Stilgenbauer, Matthias Ritgen, Sebastian Böttcher, Barbara Eichhorst & Michael Hallek. (2017) Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. The Lancet Haematology 4:10, pages e475-e486.
Crossref
Crossref